Press release

AB-Biotics and GlaxoSmithKline sign an agreement to promote the test Neurofarmagen in Brazil
Barcelona (Spain), March 21st 2013.- GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, listed on the Spanish Alternative Stock Market (MAB), have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.
"The agreement with GlaxoSmithKline will be a major boost for the AB-Biotics turnover in the coming years”, said Miquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotics.

GSK will promote in Brazil Neurofarmagen, a genetic test developed by AB-Biotics which identifies the safest and most appropriate medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. The product will be launched this year in Brazil, where according to estimates by AB-Biotics, there are 1 million potential patients eligible for Neurofarmagen. In Spain, this test is currently marketed by Almirall following the agreement signed last October by this Spanish pharmaceutical company and AB-Biotics.
Developed by Web4Bio